Long-acting opioids and short-acting opioids: Appropriate use in chronic pain management

Pain Medicine

Volumn 10, Issue SUPPL. 2, 2009, Pages

  Fine, Perry G ^a   Mahajan, Gagan ^b   Mcpherson, Mary Lynn ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Chronic; Opioid; Pain Management

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; LONG ACTING DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; OXYCODONE PLUS PARACETAMOL; OXYMORPHONE; SHORT ACTING DRUG; TRAMADOL;

ANALGESIC ACTIVITY; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; LONG TERM CARE; LOW BACK PAIN; NAUSEA; NEUROPATHIC PAIN; OPIOID INDUCED EMESIS; OSTEOARTHRITIS; PATIENT ASSESSMENT; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; PAIN; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 68449088799     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00666.x     Document Type: Review

References (63)

1. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J 2007;100(10):1028-36.
2. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008;11(suppl 2):S5-62.
3. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007;15(8):957-65.
4. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 2005;293(24):3043-52.
5. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147(7):478-91.
6. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12(1):13-21.
7. AGS Panel on Persistent Pain in older persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50(suppl 6):S205-24.
8. American Academy of Pain Medicine and American Pain Society. The use of opioids for the treatment of chronic pain. A consensus statement from American Academy of Pain Medicine and American Pain Society. Clin J Pain 1997;13(1):6-8.
9. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: A meta-analysis. Arthritis Res Ther 2006;8(5):R153.
10. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13):1324-34.
11. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26(4):862-9.
12. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15(3):179-83.
13. Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2006;2(3):155-66.
14. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132(3):237-51.
15. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28.
16. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;3: CD004959.
17. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage 2003;26(5):1026-48.
18. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: A review of the evidence. Clin J Pain 2008;24(6):469-78.
19. Chou R. Drug class review on long-acting opioid analgesics. Oregon Health and Science University (OHSU) 2006 (Final Report): 144.
20. Fine PG, Portenoy RK. A Clinical Guide to Opioid Analgesia, 2nd edition. New York: Vendome Group, LLC; 2007.
21. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63(1):17-32.
22. Glajchen M. Chronic pain: Treatment barriers and strategies for clinical practice. J Am Board Fam Pract 2001;14(3):211-18.
23. Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: Practice guidelines forinitiation and maintenance of therapy. Minerva Anestesiol 2005;71(7-8):425-33.
24. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006;22(2):173-81.
25. Smith H, Passik S, Fine PG. Opioid Risk Management. New York, NY: Oxford University Press; 2008:3-4.
26. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107-12.
27. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med 2005;6(6):432-42.
28. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain 2008;9(4):360-72.
29. Guzman J, Esmail R, Karjalainen K, et al. Multidisciplinary rehabilitation for chronic low back pain: Systematic review. BMJ 2001;322(7301):1511-16.
30. White JM, Lopatko OV. Opioid maintenance: A comparative review of pharmacological strategies. Expert Opin Pharmacother 2007;8(1):1-11.
31. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: Report of five cases. Pain 1992;49(1):87-91.
32. Walsh D. Advances in opioid therapy and formulations. Support Care Cancer 2005;13(3):138-44.
33. Opana (oxymorphone hydrochloride). Package Insert. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2006.
34. Opana ER (oxymorphone hydrochloride extended-release). Package Insert. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2008.
35. Darvon (propoxyphene hydrochloride). Package Insert. Newport, KY: Xanodyne Pharmaceuticals Inc.; 2007.
36. Ultracet (tramadol hydrochloride/acetaminophen). Package Insert. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2007.
37. Ultram ER (tramadol hydrochloride extended-release). Package Insert. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2007.
38. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: Pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8(3):181-6.
39. Caldwell JR, Rapoport RJ, Davis JC, etal. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23(4):278-91.
40. Ferrell B, Wisdom C, Wenzl C, Brown J. Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 1989;16(4):521-6.
41. Duragesic (transdermal fentanyl). Package Insert. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008.
42. McCarberg BH. The treatment of breakthrough pain. Pain Med 2007;8(suppl 1):S8-13.
43. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study. Curr Med Res Opin 2007;23(1):223-33.
44. Coluzzi PH, Schwartzberg L, Conroy JD, etal. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91(1-2):123-30.
45. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5(7):327-34.
46. Hagen NA, Fisher K, Victorino C, Farrar JT. A titration strategy is needed to manage breakthrough cancer pain effectively: Observations from data pooled from three clinical trials. J Palliate Med 2007;10(1):47-55.
47. Fentora (fentanyl buccal tablet). Package Insert. Frazer, PA: Cephalon, Inc.; 2008.
48. Actiq (fentanyl citrate oral transmucosal lozenge). Package insert. Salt Lake City, UT: Cephalon Inc.; 2007.
49. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29(4):588-601.
50. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: Patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007;8(3):281-8.
51. Salzman RT, Roberts MS, Wild J, et al. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18(4):271-9.
52. Miaskowski C, Mack KA, Dodd M, et al. Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. J Pain 2002;3(1):12-20.
53. Marshall DA, Strauss ME, Pericak D, etal. Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. Am J Manag Care 2006;12(4):205-14.
54. Hojsted J, Sjogren P. An update on the role of opioids in the management of chronic pain of nonmalignant origin. Curr Opin Anaesthesiol 2007;20(5):451-5.
55. Klepstad P, Kaasa S, Jystad A, Hval B, Borchgrevink PC. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: A randomized, double-blind trial. Pain 2003;101(1-2):193-8.
56. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2007;4: CD003868.
57. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: Novel clinical applications with related concerns. Pain Med 2002;3(4):339-48.
58. Cruciani RA, Sekine R, Homel P, et al. Measurements of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005;29(4):385-91.
59. Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: Overcoming obstacles to the use of opioids. Adv Ther 2000;17(2):70-83.
60. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: Clinical considerations. J Pain Symptom Manage 2001;21(2):144-50.
61. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005;29(suppl 5):S2-9.
62. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23(2):103-18.
63. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th edn. Glenview, IL: American Pain Society; 2003.